New perspectives in the pharmacological treatment of Hepatitis C
<p><strong>Introduction</strong>: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other l...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidad de Ciencias Médicas de La Habana
2016-09-01
|
| Series: | Revista Habanera de Ciencias Médicas |
| Online Access: | http://www.revhabanera.sld.cu/index.php/rhab/article/view/1247 |
| _version_ | 1819207671077666816 |
|---|---|
| author | Sol Gomez Aparicio Juan Vicente Esplugues Fernando Alegre Guerra |
| author_facet | Sol Gomez Aparicio Juan Vicente Esplugues Fernando Alegre Guerra |
| author_sort | Sol Gomez Aparicio |
| collection | DOAJ |
| description | <p><strong>Introduction</strong>: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other liver's diseases such as cirrhosis and the hepatocellular carcinoma. Treatment of HCV has progressed enormously in the last decade, concluding with the development of Direct-acting Antiviral Agents (DAA), which has achieved cure rates over 90%. <strong><br /> Objective:</strong> To know the different available treatments options as well as which will be available in a near future. <strong><br /> Materials and methods:</strong> Several systematic searches were made in the PubMed database; in the articles from the "liver meeting" congress of AASLD (American Association for the Study of Liver Diseases) in November 2014 and in the EASL (European Association for the Study of Liver) guide. <strong><br /> Development:</strong> The arrivals of new drugs with new therapeutic strategies have made this therapy more complex, and for that reason it is necessary to have knowledge of these drugs and their possible combinations. <strong><br /> Conclusions:</strong> The excellent results of the therapy with AAD have made a huge change in therapeutic recommendations, making possible shorter therapies, better tolerated by patients and safer for health.</p><p><strong>Keywords</strong>: Hepatitis C virus, genotypes, direct acting antivirals, pharmacotherapy, mechanism of action, sofosbuvir, sustained virological response.</p> |
| first_indexed | 2024-12-23T05:27:12Z |
| format | Article |
| id | doaj.art-75dde1d21a33431485080a265b0804c3 |
| institution | Directory Open Access Journal |
| issn | 1729-519X |
| language | English |
| last_indexed | 2024-12-23T05:27:12Z |
| publishDate | 2016-09-01 |
| publisher | Universidad de Ciencias Médicas de La Habana |
| record_format | Article |
| series | Revista Habanera de Ciencias Médicas |
| spelling | doaj.art-75dde1d21a33431485080a265b0804c32022-12-21T17:58:34ZengUniversidad de Ciencias Médicas de La HabanaRevista Habanera de Ciencias Médicas1729-519X2016-09-01155724743631New perspectives in the pharmacological treatment of Hepatitis CSol Gomez Aparicio0Juan Vicente Esplugues1Fernando Alegre Guerra2Universidad de Valencia, España Facultad de Medicina Departamento de FarmacologíaUniversidad de Valencia, España Facultad de Medicina Departamento de FarmacologíaUniversidad de Valencia, España Facultad de Medicina Departamento de Farmacología<p><strong>Introduction</strong>: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other liver's diseases such as cirrhosis and the hepatocellular carcinoma. Treatment of HCV has progressed enormously in the last decade, concluding with the development of Direct-acting Antiviral Agents (DAA), which has achieved cure rates over 90%. <strong><br /> Objective:</strong> To know the different available treatments options as well as which will be available in a near future. <strong><br /> Materials and methods:</strong> Several systematic searches were made in the PubMed database; in the articles from the "liver meeting" congress of AASLD (American Association for the Study of Liver Diseases) in November 2014 and in the EASL (European Association for the Study of Liver) guide. <strong><br /> Development:</strong> The arrivals of new drugs with new therapeutic strategies have made this therapy more complex, and for that reason it is necessary to have knowledge of these drugs and their possible combinations. <strong><br /> Conclusions:</strong> The excellent results of the therapy with AAD have made a huge change in therapeutic recommendations, making possible shorter therapies, better tolerated by patients and safer for health.</p><p><strong>Keywords</strong>: Hepatitis C virus, genotypes, direct acting antivirals, pharmacotherapy, mechanism of action, sofosbuvir, sustained virological response.</p>http://www.revhabanera.sld.cu/index.php/rhab/article/view/1247 |
| spellingShingle | Sol Gomez Aparicio Juan Vicente Esplugues Fernando Alegre Guerra New perspectives in the pharmacological treatment of Hepatitis C Revista Habanera de Ciencias Médicas |
| title | New perspectives in the pharmacological treatment of Hepatitis C |
| title_full | New perspectives in the pharmacological treatment of Hepatitis C |
| title_fullStr | New perspectives in the pharmacological treatment of Hepatitis C |
| title_full_unstemmed | New perspectives in the pharmacological treatment of Hepatitis C |
| title_short | New perspectives in the pharmacological treatment of Hepatitis C |
| title_sort | new perspectives in the pharmacological treatment of hepatitis c |
| url | http://www.revhabanera.sld.cu/index.php/rhab/article/view/1247 |
| work_keys_str_mv | AT solgomezaparicio newperspectivesinthepharmacologicaltreatmentofhepatitisc AT juanvicenteesplugues newperspectivesinthepharmacologicaltreatmentofhepatitisc AT fernandoalegreguerra newperspectivesinthepharmacologicaltreatmentofhepatitisc |